Premium
The effect of Ecklonia cava supplement on blood lipid profiles in hyperlipidemic Koreans: a 12‐week, randomized, double‐blind, placebo‐controlled clinical trial (642.7)
Author(s) -
Park EunOck,
Choi EunKyung,
Kim SunYoung,
Park SooHyun,
Oh MiRa,
Jung EunSoo,
Jang YoonJin,
Chae SooWan,
Kim Seong Ho,
Shin HyeonCheol,
Park TaeSun
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.642.7
Subject(s) - placebo , medicine , triglyceride , cholesterol , clinical endpoint , lipid profile , randomized controlled trial , blood lipids , adverse effect , gastroenterology , endocrinology , pathology , alternative medicine
This study examined effect and safety of Ecklonia cava supplement on blood lipid metabolism in hyperlipidemic subjects. This study was a 12‐weeks, randomized, double‐blind, placebo‐controlled clinical trial. Inclusion criteria were age of 19 to 80 years and total cholesterol level蠅200mg/dL or LDL‐cholesterol level蠅110mg/dL. Eighty subjects were randomly assigned to two treatment groups: Ecklonia cava (SEPOLYNOL 400mg/day) and placebo group. The primary endpoint was total and LDL‐cholesterol level. Secondary endpoint was triglyceride and HDL‐cholesterol level. After 12 weeks of treatment, total cholesterol and LDL‐cholesterol of test group was significantly improved compared with those of placebo group ( p =0.039, p =0.030). HDL‐cholesterol in test group showed a significant decrease compared with those of placebo group statistically ( p =0.021), but not clinically. There were no significant adverse events relating to this trial. In conclusion, these results demonstrate that Ecklonia cava supplementation is considered to be safe and beneficial for improving blood lipid profiles by lowering total and LDL‐cholesterol with safety in hyperlipidemic subjects.